9 November 2022 ORYZON announces FDA clearance of IND to initiate a collaborative Phase II basket study with iadademstat in R/R patients with Neuroendocrine carcinomas (NECs)
7 November 2022 ORYZON announces oral data presentation at the upcoming 64th American Society of Hematology annual conference